These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 27173027)

  • 1. Fibronectin-1 expression is increased in aggressive thyroid cancer and favors the migration and invasion of cancer cells.
    Sponziello M; Rosignolo F; Celano M; Maggisano V; Pecce V; De Rose RF; Lombardo GE; Durante C; Filetti S; Damante G; Russo D; Bulotta S
    Mol Cell Endocrinol; 2016 Aug; 431():123-32. PubMed ID: 27173027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect and clinical significance of FN1 expression on biological functions of gastric cancer cells.
    Zhou Y; Cao G; Cai H; Huang H; Zhu X
    Cell Mol Biol (Noisy-le-grand); 2020 Jul; 66(5):191-198. PubMed ID: 33040835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twist1 regulates the epithelial-mesenchymal transition via the NF-κB pathway in papillary thyroid carcinoma.
    Lv N; Shan Z; Gao Y; Guan H; Fan C; Wang H; Teng W
    Endocrine; 2016 Mar; 51(3):469-77. PubMed ID: 26289126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Podoplanin (PDPN) affects the invasiveness of thyroid carcinoma cells by inducing ezrin, radixin and moesin (E/R/M) phosphorylation in association with matrix metalloproteinases.
    Sikorska J; Gaweł D; Domek H; Rudzińska M; Czarnocka B
    BMC Cancer; 2019 Jan; 19(1):85. PubMed ID: 30654768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF(V600E) mutation and the biology of papillary thyroid cancer.
    Frasca F; Nucera C; Pellegriti G; Gangemi P; Attard M; Stella M; Loda M; Vella V; Giordano C; Trimarchi F; Mazzon E; Belfiore A; Vigneri R
    Endocr Relat Cancer; 2008 Mar; 15(1):191-205. PubMed ID: 18310287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR6 predicts poor prognosis in gastric cancer and promotes tumor metastasis through epithelial-mesenchymal transition.
    Jin JJ; Dai FX; Long ZW; Cai H; Liu XW; Zhou Y; Hong Q; Dong QZ; Wang YN; Huang H
    Oncol Rep; 2017 Jun; 37(6):3279-3286. PubMed ID: 28440473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uridine phosphorylase 1 associates to biological and clinical significance in thyroid carcinoma cell lines.
    Guan Y; Bhandari A; Zhang X; Wang O
    J Cell Mol Med; 2019 Nov; 23(11):7438-7448. PubMed ID: 31496029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma.
    Chou CK; Yang KD; Chou FF; Huang CC; Lan YW; Lee YF; Kang HY; Liu RT
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E196-205. PubMed ID: 23264400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
    Nicolussi A; D'Inzeo S; Mincione G; Buffone A; Di Marcantonio MC; Cotellese R; Cichella A; Capalbo C; Di Gioia C; Nardi F; Giannini G; Coppa A
    Int J Oncol; 2014 Feb; 44(2):548-56. PubMed ID: 24316730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.
    Feng C; Gao Y; Wang C; Yu X; Zhang W; Guan H; Shan Z; Teng W
    J Clin Endocrinol Metab; 2013 Sep; 98(9):E1524-33. PubMed ID: 23846818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion.
    Vasko V; Espinosa AV; Scouten W; He H; Auer H; Liyanarachchi S; Larin A; Savchenko V; Francis GL; de la Chapelle A; Saji M; Ringel MD
    Proc Natl Acad Sci U S A; 2007 Feb; 104(8):2803-8. PubMed ID: 17296934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
    Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
    Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW
    Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF-α increases the membrane expression of the chemokine receptor CCR6 in thyroid tumor cells, but not in normal thyrocytes: potential role in the metastatic spread of thyroid cancer.
    Coperchini F; Pignatti P; Carbone A; Bongianino R; Di Buduo CA; Leporati P; Croce L; Magri F; Balduini A; Chiovato L; Rotondi M
    Tumour Biol; 2016 Apr; 37(4):5569-75. PubMed ID: 26577851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-200c binding to FN1 suppresses the proliferation, migration and invasion of gastric cancer cells.
    Zhang H; Sun Z; Li Y; Fan D; Jiang H
    Biomed Pharmacother; 2017 Apr; 88():285-292. PubMed ID: 28113080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-663 suppresses cell invasion and migration by targeting transforming growth factor beta 1 in papillary thyroid carcinoma.
    Wang Z; Zhang H; Zhang P; Dong W; He L
    Tumour Biol; 2016 Jun; 37(6):7633-44. PubMed ID: 26687649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WSTF promotes proliferation and invasion of lung cancer cells by inducing EMT via PI3K/Akt and IL-6/STAT3 signaling pathways.
    Meng J; Zhang XT; Liu XL; Fan L; Li C; Sun Y; Liang XH; Wang JB; Mei QB; Zhang F; Zhang T
    Cell Signal; 2016 Nov; 28(11):1673-82. PubMed ID: 27449264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of long noncoding RNA LOC100507661 promotes tumor aggressiveness in thyroid cancer.
    Kim D; Lee WK; Jeong S; Seol MY; Kim H; Kim KS; Lee EJ; Lee J; Jo YS
    Mol Cell Endocrinol; 2016 Aug; 431():36-45. PubMed ID: 27151833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitofusin-2 modulates the epithelial to mesenchymal transition in thyroid cancer progression.
    You MH; Jeon MJ; Kim SR; Lee WK; Cheng SY; Jang G; Kim TY; Kim WB; Shong YK; Kim WG
    Sci Rep; 2021 Jan; 11(1):2054. PubMed ID: 33479369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.